FOR MEDICAL WEIGHT MANAGEMENT

Lose Fat. Not Muscle.

A targeted essential amino acid protocol to counteract GLP-1-associated sarcopenia, preserve lean mass, and optimise metabolic rate.

The Clinical Challenge

GLP-1 receptor agonists (semaglutide, tirzepatide) are transforming medical weight management. However, clinical trials reveal a significant complication regarding body composition.1

40%
of the total weight lost on GLP-1 therapy can be lean muscle mass.2
3X
greater muscle protein synthesis with leucine-enriched EAAs vs intact protein.3

This muscle loss leads to a decreased metabolic rate, fatigue, and an increased risk of weight regain. Furthermore, the profound gastrointestinal fullness induced by GLP-1 therapies makes it physically difficult for patients to consume adequate dietary whole protein.4

Bypassing the Gi Burden

Rebound Recover is a physician-formulated Essential Amino Acid (EAA) complex designed to support the mTORC1 pathway for muscle protein synthesis. Because they are free-form, they absorb instantly, requiring zero digestion and bypassing GLP-1-induced delayed gastric emptying.5

The Rebound Protocol

Rebound is a physician-formulated, three-phase perioperative nutrition protocol designed to optimise surgical outcomes and accelerate patient recovery for patients on GLP-1 receptor agonists.

Rebound READY (Pre-op)

Reduces surgical insulin resistance and postoperative nausea (PONV) through targeted clear-liquid carbohydrate loading before theatre.1,2

Rebound RECOVER (Post-op)

Delivers a precise Essential Amino Acid (EAA) complex, supporting the mTORC1 pathway to preserve muscle mass and combat surgical catabolism without causing gastrointestinal fullness.3,4

Rebound RESTORE (Healing)

Provides targeted micronutrients to support bone density, joint cartilage, and long-term tissue repair.5

Clinical Integration

Unlike high whole-protein diets (>1.5 g/kg/day) which can cause glomerular hyperfiltration, free-form EAAs provide anabolic triggers without the full nitrogenous waste burden, which may be relevant for patients with Type 2 diabetes and hypertension.6

Clinical studies demonstrate that during caloric restriction, only complete EAA formulas significantly increase muscle mass (+2.84 kg), whereas whole protein supplements and BCAAs alone fail to preserve lean mass compared to control.1

Clinical Evidence

  1. Fitch A, Gigliotti L, Bays HE. Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. Obes Pillars. 2025;16:100205. doi:10.1016/j.obpill.2025.100205.
  2. Ceasovschih A, Asaftei A, Lupo MG, et al. Glucagon-like peptide-1 receptor agonists and muscle mass effects. Pharmacol Res. 2025;220:107927. doi:10.1016/j.phrs.2025.107927.
  3. Cannavaro D, Leva F, Caturano A, et al. Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation. Nutrients. 2025;17(12):2000. doi:10.3390/nu17122000.
  4. Sandha TS, Ron O, Rozen WM, Seth I, Cuomo R. Perioperative Nutrition and Surgical Outcomes in Patients Receiving Glucagon-like Peptide-1 Receptor Agonists: A Scoping Review. Medicina. 2026;62(8):1434. doi:10.3390/medicina62081434.
  5. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(S4):16-27. doi:10.1111/dom.15728.
  6. Alawadhi AA, Al-Mulla A, Al-Ozairi E, et al. LEAN mass Preservation with Resistance Exercise and Protein Supplementation in Obese Individuals with Type 2 Diabetes on GLP-1 Receptor Agonists (LEAN-GLP-1): A Randomized Controlled Trial. PMC. 2026;PMC13110620.
READY • RECOVER • RESTORE • THRIVE